C. James, V. Ugo, L. Couedic, J. P. Staerk, J. Delhommeau et al., A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera, Nature, vol.434, issue.7037, pp.1144-1148, 2005.

E. J. Baxter, L. M. Scott, P. J. Campbell, C. East, N. Fourouclas et al., Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders, Cancer Genome P, vol.365, issue.9464, pp.71142-71151, 2005.

R. Kralovics, F. Passamonti, A. S. Buser, S. S. Teo, R. Tiedt et al., A gain-of-function mutation of JAK2 in myeloproliferative disorders, N Engl J Med, vol.352, issue.17, pp.1779-1790, 2005.

R. L. Levine, M. Wadleigh, J. Cools, B. L. Ebert, G. Wernig et al., Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis, Cancer Cell, vol.7, issue.4, pp.387-397, 2005.

E. Lippert, M. Boissinot, R. Kralovics, F. Girodon, I. Dobo et al., The JAK2V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera, Blood, vol.108, issue.6, pp.1865-1867, 2006.

F. Passamonti, E. Rumi, P. D. , D. Porta, M. G. Boveri et al., Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders, Blood, vol.107, issue.9, pp.3676-3682, 2006.

J. J. Kiladjian, B. Cassinat, S. Chevret, P. Turlure, N. Cambier et al., Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera, Blood, vol.112, issue.8, pp.3065-3072, 2008.

J. V. Jovanovic, A. Ivey, A. M. Vannucchi, E. Lippert, O. Leibundgut et al., Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study, Leukemia, vol.27, issue.10, pp.2032-2039, 2013.

C. Utke-rank, W. Bjerrum, O. Larsen, T. S. Kjaer, L. De-stricker et al., Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera, Leuk Ann Hematol Lymphoma, vol.57, pp.1-7, 2015.

A. J. Bench, H. E. White, L. Foroni, A. L. Godfrey, G. G. Akiki et al., British Committee for Standards in H (2013) Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations, Br J Haematol, vol.160, issue.1, pp.25-34

E. Lippert, F. Girodon, E. Hammond, J. Jelinek, N. S. Reading et al., Concordance of assays designed for the quantification of JAK2V617F: a multicenter study, Haematologica, vol.94, issue.1, pp.38-45, 2009.

M. Perricone, F. Palandri, E. Ottaviani, M. Angelini, L. Bagli et al., Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: a study involving a consortium of 19 Italian laboratories, Oncotarget, vol.8, pp.32608-32617, 1920.

T. S. Larsen, J. H. Christensen, H. C. Hasselbalch, and N. Pallisgaard, The JAK2 V617F mutation involves B-and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders, Br J Haematol, vol.136, issue.5, pp.745-751, 2007.

C. C. Raggi, P. Verderio, M. Pazzagli, E. Marubini, L. Simi et al., An Italian program of external quality control for quantitative assays based on real-time PCR with TaqMan probes, Clin Chem Lab Med: CCLM / FESCC, vol.43, issue.5, pp.542-548, 2005.

S. Hermouet, I. Dobo, E. Lippert, M. C. Boursier, L. Ergand et al., Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2(V617F), Leukemia, vol.21, issue.5, pp.1128-1130, 2007.

T. P. Hughes, J. Kaeda, S. Branford, Z. Rudzki, A. Hochhaus et al., International Randomised Study of Interferon versus STISG (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia, N Engl J Med, vol.349, issue.15, pp.1423-1432

T. Hughes, M. Deininger, A. Hochhaus, S. Branford, J. Radich et al., Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results, Blood, vol.108, issue.1, pp.28-37, 2006.

H. E. White, P. Matejtschuk, P. Rigsby, J. Gabert, F. Lin et al., Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA, Blood, vol.116, issue.22, pp.111-117, 2010.

H. White, L. Deprez, P. Corbisier, V. Hall, F. Lin et al., A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by realtime quantitative PCR, Leukemia, vol.29, issue.2, pp.369-376, 2015.

P. Sanzone, R. Hawkins, P. Rigsby, and J. Boyle, Collaborative study to evaluate the proposed WHO 1st International Reference Panel for Genomic JAK2 V617F, 2016.